Armistice Capital’s XORTX Therapeutics XRTX Stock Holding History

Armistice Capital’s Portfolio XRTX Stock Details XRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-53,000	Closed	-$299K	–	285
2024 Q4	$299K	Buy	+53,000	New	+$366K	﹤0.01%	186
2023 Q1	–	Sell	-3,686	Closed	-$1.21M	–	255
2022 Q4	$1.21M	Buy	+3,686	New	+$1.31M	0.02%	126

Other funds holding XRTX

Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Armistice Capital's XRTX Position: Q1 2025 in Review

Armistice Capital sold out of XORTX Therapeutics (XRTX) in Q1 2025, closing a stake of 53,000 shares — an estimated $299K sold.

Armistice Capital first reported a position in XRTX in Q4 2022 and held it in 2 quarters. The position peaked at $1.21M in Q4 2022. 2 funds tracked by Wall St. Rank hold XRTX as of Q1 2025.

Armistice Capital reported no remaining XORTX Therapeutics position as of Q1 2025 after selling out during the quarter.
Armistice Capital sold 53,000 XORTX Therapeutics shares in Q1 2025, an estimated $299K.
Armistice Capital first reported a position in XORTX Therapeutics in Q4 2022 and held it in 2 quarters.
Armistice Capital's XORTX Therapeutics position peaked at $1.21M in Q4 2022.
2 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.